WCG Clinical, Inc.acquired VeraSci for $330 million on July 20, 2021. WCG Clinical acquired all the outstanding shares of VeraSci for a purchase price of $330 million in cash, which was funded, along with transaction fees and expenses, by $200 million of term loan borrowings pursuant to the Third Amendment and $140 million of borrowings under the Revolving Credit Facility. Moving forward, VeraSci will be known as WCG VeraSci. The organization will retain its leadership structure and continue to operate from its headquarters in North Carolina. Robert W. Baird & Co. Incorporated acted as financial advisor to VeraSci on this transaction. Kevin Shmelzer of Morgan, Lewis & Bockius LLP acted as legal advisor to WCG Clinical, Inc. WCG Clinical, Inc. completed the acquisition of VeraSci on July 20, 2021.